TCGA-H4-A2HQ-01A-11R-A180-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.38239159
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- G2M_CHECKPOINT+0.360
- E2F_TARGETS+0.310
- MITOTIC_SPINDLE+0.310
- TGF_BETA_SIGNALING+0.300
- INTERFERON_ALPHA_RESPONSE+0.290
- MYC_TARGETS_V1+0.260
- MTORC1_SIGNALING+0.250
- DNA_REPAIR+0.230
- WNT_BETA_CATENIN_SIGNALING+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- ANGIOGENESIS-0.460
- ALLOGRAFT_REJECTION-0.410
- INFLAMMATORY_RESPONSE-0.410
- COAGULATION-0.380
- MYOGENESIS-0.330
- XENOBIOTIC_METABOLISM-0.300
- KRAS_SIGNALING_UP-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
- APICAL_SURFACE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.837 |
| 2 | TCGA-C8-A1HK-01A-21R-A13Q-07 | — | C | 0.829 |
| 3 | BS_DFGS950G | high-grade glioma | — | 0.827 |
| 4 | 61F5C72A-4DDB-4EDB-908A-B2856CAFD8BD | — | — | 0.826 |
| 5 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.826 |
| 6 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.824 |
| 7 | TCGA-78-7536-01A-11R-2066-07 | — | cohortA3 | 0.824 |
| 8 | B8B72B5C-536A-40E3-9E7F-95E7629874D3 | — | — | 0.817 |
| 9 | BS_FN07P04C | high-grade glioma | — | 0.814 |
| 10 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |